Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

NCT02582242 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02582242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02582242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
October 19, 2015
Completion date
April 18, 2017
Enrollment
437 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, type 2 diabetes mellitus